Mariner Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mariner Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-76,872	Closed	-$5.98M	–	92
2016 Q2	$5.98M	Buy	76,872 +200	+0.3%	+$17K	2.02%	14
2016 Q1	$6.32M	Buy	76,672 +27,600	+56%	+$2.25M	1.74%	12
2015 Q4	$5.14M	Buy	49,072 +43,616	+799%	+$4.55M	1.14%	23
2015 Q3	$575K	Buy	+5,456	New	+$729K	0.12%	145
2015 Q1	–	Sell	-12,856	Closed	-$1.36M	–	184
2014 Q4	$1.16M	Buy	12,856 +1,500	+13%	+$125K	0.2%	105
2014 Q3	$819K	Sell	11,356 -9,794	-46%	-$644K	0.17%	116
2014 Q2	$1.32M	Buy	21,150 +13,000	+160%	+$785K	0.25%	97
2014 Q1	$556K	Buy	+8,150	New	+$601K	0.12%	117

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mariner Investment Group's BMRN Position: Q3 2016 in Review

Mariner Investment Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2016, closing a stake of 76,872 shares — an estimated $5.98M sold.

Mariner Investment Group first reported a position in BMRN in Q1 2014 and held it in 8 quarters. The position peaked at $6.32M in Q1 2016. 422 funds tracked by Wall St. Rank hold BMRN as of Q3 2016.

Mariner Investment Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Mariner Investment Group sold 76,872 BioMarin Pharmaceuticals shares in Q3 2016, an estimated $5.98M.
Mariner Investment Group first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Mariner Investment Group's BioMarin Pharmaceuticals position peaked at $6.32M in Q1 2016.
422 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2016.

Based on Mariner Investment Group's 13F filing for Q3 2016, filed 3 Nov 2016.